Sana Biotechnology

### Executive Summary Sana Biotechnology raised $175.4M via a Rule 506(c) private placement, with first sale on 2025-10-12. Key related persons include Andreessen Horowitz and Sands Capital, signaling strong institutional backing for its synthetic biology and intracellular mRNA delivery platform. ### Investor Edge Monitor for a follow-on Form D/A, which could reveal pricing changes or new investors — the first sale date is eight months prior to today, suggesting a possible bridging round or closing tranche. ### Sector capital positioning The $175.4M raise in synthetic biology and intracellular mRNA delivery reflects sustained private capital appetite for next-gen precision therapeutics. ### Convergence Signals No direct public signals (patents, contracts, legislation) evident in this filing. The sector convergence is primarily in chronic and rare disease therapeutics where mRNA delivery is a key enabler. ### Key Takeaways - Sana Biotechnology raised $175.4M in a private placement with blue-chip investors listed as related persons. - The raise is in synthetic biology and intracellular mRNA delivery, a high-conviction sector for private capital. - The time lag between first sale and filing suggests the offering may be partially subscribed or in tranches; an amended filing could provide more detail. ### Risk Indicators & Flags No D/A amendments on record. No regulatory flags visible. The $175.4M amount is sizeable for a synthetic biology platform, but not outlier concerning the sector's capital intensity. ### Verification & References Filing type is Form D (not D/A), first sale 2025-10-12; related persons are SEC-registered officers/directors, not necessarily the capital source. Accession number 0001702600-24-20071. Verify at SEC EDGAR under company name 'Sana Biotechnology', form type D.